By  Eunjoo Cho

Received: 2024-8-23 / Accepted: 2024-9-23 / Published: 2024-9-27

PDF Main Manuscript (555.04 KB)  DOI: https://doi.org/10.37906/isteamc.2024.5

Abstract Alzheimer’s disease is a major type of dementia characterized by progressive neurodegeneration that leads to cognitive decline and brain atrophy. The progression of the disease is marked by the accumulation of amyloid β plaques and tau tangles that are proposed to be the driver of subsequent neural death and atrophy. Targeting these hallmarks with monoclonal antibodies has become a promising approach to treating Alzheimer’s disease. As of 2021, the FDA approved the amyloid β targeting monoclonal antibody aducanumab as the first approved treatment for Alzheimer’s disease. Since this landmark, significant work has been done to develop monoclonal antibodies to treat Alzheimer’s disease. In this review, we discuss the development of FDA-approved monoclonal antibodies aducanumab, lecanemab, and donanemab, as well as the monoclonal antibodies remternetug and E2814 that are currently in late-phase clinical trials. [More...]

By  Yuhan Zhong

Received: 2024-6-8 / Accepted: 2024-9-6 / Published: 2024-9-10

PDF Main Manuscript (919.9 KB)  DOI: https://doi.org/10.37906/isteamc.2024.6

Abstract Music, in all its diverse forms, transcends strict boundaries and communicates a universal language that unites people across cultures, histories, and personal experiences. This journey is a vibrant fusion of sounds, rhythms, and traditions, blending elements from various musical genres and cultures worldwide. Beginning in the early 20th century, compositions like Scott Joplin’s “Maple Leaf Rag” reshaped the landscape of classical music. Indie musicians such as the Buena Vista Social Club further expanded these limits, merging Latin classics with innovative new styles of musical production. Moving into the 21st century, artists like Depeche Mode continue to astonish listeners with electronic beats that capture the essence of contemporary digital music. [More...]